Secondary prevention of myocardial infarction in the first European Stroke Prevention Study.
The first European Stroke Prevention Study (ESPS 1) showed that a statistically significant degree of secondary ischemic lesions could be prevented by combined therapy with aspirin (330 mg) and dipyridamole (75 mg) t.i.d. The risk of both central and myocardial secondary ischemic lesions was reduced by more than 30%. Similar results were seen after both transient ischemic attacks and stroke, and in both men and women.
Lowenthal
A
A
Algemeen Ziekenhuis Middelheim, Antwerp, Belgium.
D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use*; D002561:Cerebrovascular Disorders / Q000517:prevention & control*; D004176:Dipyridamole / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005060:Europe; D006801:Humans; D009203:Myocardial Infarction / Q000517:prevention & control*
D004176:Dipyridamole; D001241:Aspirin